Brief: Vaxcyte Provides Clinical, Regulatory Progress Update On Pneumococcal Conjugate Vaccine Franchise

Vaxcyte

04/01/2024 21:48

Jan 4 (Reuters) - Vaxcyte Inc  PCVX.O :
    * VAXCYTE PROVIDES CLINICAL AND REGULATORY PROGRESS UPDATE
ON
POTENTIAL BEST-IN-CLASS PNEUMOCOCCAL CONJUGATE VACCINE (PCV)
FRANCHISE
    * VAXCYTE INC - COMPANY OUTLINES EXPECTED PHASE 3 TIMELINES
FOR
VAX-24 AND VAX-31 ADULT PROGRAMS
    * VAXCYTE INC - ENROLLMENT IN ONGOING VAX-24 INFANT PHASE 2
STUDY
CONTINUES TO PROGRESS
    * VAXCYTE INC - TOPLINE DATA FROM PRIMARY IMMUNIZATION
SERIES
EXPECTED BY END OF Q1 OF 2025, FOLLOWED BY TOPLINE DATA FROM
BOOSTER DOSE BY END OF 2025
    * VAXCYTE:DOSES FIRST PARTICIPANTS IN PHASE 2 PORTION OF
ONGOING
VAX-31 PHASE 1/2 STUDY IN ADULTS

Source text for Eikon:  ID:nGNX9N0kp7 
Further company coverage:  PCVX.O